PT-141
Bremelanotide · Vyleesi
FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, with off-label research in men.
Half-Life
~2.7 hours
MW
1025.2 Da
Amino Acids
7 AA
Evidence
High Evidence
Regulatory Status
FDA-approved (Vyleesi) for HSDD in premenopausal women. Research for male sexual dysfunction.
In Plain English
Works in the brain — not in blood vessels like Viagra — to trigger sexual arousal. Activates melanocortin receptors in the hypothalamus to increase desire and arousal centrally. FDA-approved (Vyleesi) for low sexual desire in women.
Overview
PT-141 (Bremelanotide, Vyleesi) is a cyclic heptapeptide melanocortin receptor agonist. The first FDA-approved drug to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally (brain) to increase sexual desire rather than peripherally like PDE5 inhibitors.
Common Formats
- Auto-injector pen (approved)
- Lyophilized powder (compounded/research)
Storage Notes
Refrigerate 2-8°C.
Looking for multi-compound protocols?
Browse educational protocol discussions that include PT-141.
Research Sources
(5 vendors)For research use only. No affiliation or endorsement implied.
Related Compounds
Kisspeptin
An endogenous neuropeptide and master regulator of the HPG axis, GnRH release, and reproductive function with significant clinical research interest.
Melanotan II
A cyclic alpha-MSH analogue with potent melanogenic, sexual arousal, and appetite-suppressing effects through broad melanocortin receptor activation.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.